Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2013

View Archived Issues

The discovery and preclinical validation of a potent antitumor peptide vaccine

ONO-6950 shows potential as a novel therapeutic option for bronchial asthma

Researchers from Kineta present novel broad-spectrum antiviral compounds

MedImmune presents results for MEDI-565 and MEDI-575

Medigene and SynCore extend agreement for anticancer candidate

FDA tests potential universal influenza vaccine

Analysis of LRG glycosylation allows for improved diagnostic accuracy in HF

Researchers present preclinical results for leukadherin-1

New TRPV1 ligands patented by Grunenthal

New bispecific antibody fusion proteins disclosed by UCB

Genentech presents new series of BTK inhibitors

Merck & Co. discloses new mGlu2 receptor antagonists

Researchers at Theravance design novel HCV NS5A inhibitors

Cellmid completes acquisition of Advangen

Phase I/IIa study of dendritic cell-based vaccine for AML meets endpoints

Arrowhead Research plans phase I study of ARC-520 for chronic HBV infection

Cellular Dynamics licenses rights to develop cardiomyocyte progenitors for therapeutic use

FDA grants breakthrough therapy designation to Alexion's asfotase alfa

Stribild receives European approval

Nouriast set to launch in Japan

Pharmstandard increases stake in Biolek

FDA issues complete response letter for Valeant's efinaconazole

Omeros plans European phase I study of OMS-721 for atypical hemolytic uremic syndrome

Aslan reports positive data from phase II ALSAN-001 study

First clinical study of Bionor Pharma's HIV vaccine candidate Vacc-C5 completes enrollment

Cenix BioScience to identify predictive biomarkers for Debiopharm's oncology candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...